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Effects of long-term treatment with an inhaled 
corticosteroid on growth and pulmonary function in 
asthmatic children 
L. AGERTOFT AND S. FEDERSEN 
Department of Paediatrics, Kolding Hospital, DK-6000 Koldimg, Denmark 
In a controlled prospective study we have measured growth and pulmonary function in children with asthma 
during long-term treatment with inhaled budesonide and compared these findings with those obtained from 
children not treated with corticosteroids. Two hundred and sixteen children were followed at 6 monthly 
intervals for 1-2 years without inhaled budesonide and then for 3-6 years on inhaled budesonide. Sixty-two 
children treated with theophylline, &agonists and sodiumcromoglycate but not with inhaled steroids were 
also followed for 3-7 years (controls). 
During the period of budesonide therapy the mean daily dose decreased from 710 to 430,~g (PcO.01) and 
no signs of tachyphylaxis to the treatment were seen. Budesonide treatment was associated with a significant 
reduction in the number of annual hospital admissions due to acute severe asthma (from 0.03 to 0.004 per 
child, P<O.OOl). In patients not treated with budesonide an annual decrease in % predicted FEV, of l-3% was 
seen. In contrast FEV, improved significantly with time during budesonide treatment, both compared with the 
run-in period and with the control group (P<O.Ol). Furthermore, there was a significant (P=O.Ol) relationship 
between the duration of asthma at the start of budesonide and the annual increase in FEV, during budesonide 
therapy. After 3 years of treatment with budesonide, children who started this therapy later than 5 years after 
the onset of asthma had significantly lower FEV, (96%) than the children who received budesonide within 
the first 2 years after the onset of asthma (101%) (P<O.O5). No statistically significant changes in growth 
velocity (run-in=56 cm year-‘, controls=5.6 cm year- ‘, budesonide=5.5 cm year- ‘) or weight gain (run-in= 
3.5 kg year-‘, controls=3.6 kg year-‘, budesonide=3.6 kg year-‘) were seen during budesonide treatment. 
We conclude that inhaled budesonide in doses up to 400 pg per day does not stunt growth in children with 
asthma and that early intervention with this treatment may prevent the development of irreversible airway 
obstruction and reduce the risk of under-treatment. Finally, continuous long-term treatment is not associated 
with the development of tachyphylaxis. 
Introduction 
Because of their clinical efficacy and anti- 
inflammatory properties, inhaled corticosteroids are 
now accepted as first line treatment of asthma in 
adults, even in patients with mild symptoms (1,2). 
Inhaled corticosteroids are not yet as widely accepted 
in the treatment of children with asthma (3), and a 
fear of systemic side effects, such as stunting of 
growth, is one major reason. 
For many years, inhaled corticosteroids were 
reserved for patients with severe asthma in our clinic. 
Remaining children were treated with inhaled or 
systemic &agonists, theophylline, or sodiumcro- 
moglycate (SCG) as recommended for children with 
mild and moderate asthma (3). In 1986 this strategy 
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changed and inhaled glucocorticosteroids were to be 
introduced earlier in the course of treatment. When 
the change occurred, we designed the present study to 
assess statural growth, weight, pulmonary function, 
number of hospital admissions due to acute severe 
asthma, and dose of inhaled corticosteroid required 
in children with asthma during long-term inhaled 
corticosteroid treatment and to compare the mea- 
surements with those obtained in children in whom 
inhaled corticosteroids were not given. 
Patients and Methods 
Children with mild and moderate asthma and no 
other chronic disease were studied. To be included, 
the children had to have visited the clinic at 6 months 
intervals for at least 1 year (three visits). During this 
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period, the children were to have been treated accord- 
ing to the normally recommended guidelines (3) and 
not to have used inhaled or oral corticosteroids for 
more than 2 weeks per year. This corticosteroid-free 
period is referred to as the ‘run-in’ period. 
After the run-in, the children started treatment 
with inhaled budesonide 800 pg day-’ for 6-8 weeks 
to establish optimal or acceptable asthma control. If 
optimal control was achieved the budesonide dose 
was gradually reduced by 25% at monthly intervals 
until acceptable control had been established and the 
dose remained at that level until the next clinic visit. 
If the initial budesonide treatment did not result in 
optimal or acceptable control and compliance was 
assessed to be good, the budesonide dose was 
increased and/or other treatment (theophylline or 
oral &agonists) added. Inhaled &agonists were 
always taken morning and evening and p.r.n. The 
effect of changing the budesonide dose was moni- 
tored by diary recordings and PEF measurements at 
home before and 3-6 weeks after each change. Often 
these measurements were supplemented with lung 
function measurement at the hospital. Furthermore, 
throughout the study a standardized exercise test was 
used at the discretion of the clinician to assess the 
bronchial hyperreactivity of the child. Treatment 
with (SCG) was always stopped when budesonide 
treatment was started. 
Asthma control was defined as optimal when four 
of the following criteria were fulfilled: 
(a) The child leads a normal life, including normal 
physical activity. 
(b) Use of rescue terbutaline < 1 per week. 
(c) Diurnal variation in PEF 110% on 2 5 days 
per week. 
(d) Asthma symptoms <once a week. 
(e) PEF and/or FEV, 2 100% of predicted 
normal. 
(I) < 10% fall in FEV, after a standardization 
exercise test (if performed). 
When control was optimal a reduction in budesonide 
dose was attempted. 
Asthma control was defined as acceptable when 
four of the following criteria were fulfilled: 
(a) The child leads a normal life, including normal 
physical activity. 
(b) Use of rescue terbutaline 13 per week. 
(c) Diurnal variation in PEF <lo% on 2 5 days 
per week. 
(d) Asthma symptoms <3 days per week. 
(e) PEF and/or FEV, 290% of the patient’s best. 
(f) ~20% fall in FEV, after a standardized exercise 
test (if performed). 
When control was acceptable no changes in budes- 
onide dose were made. 
Asthma control was considered as unacceptable 
when the criteria for acceptable control were not 
fulfilled. In that case the budesonide dose was 
increased or other treatment added. 
If any of the following criteria: 
(a) A fall in morning PEF >20%. 
(b) Use of >5 inhalations of rescue terbutaline. 
(c) >one-step worsening in symptom score (i.e. 
from 0 to 2 or from 1 to 3). 
were fulfilled on each of each of three consecutive 
days the dose of budesonide was doubled until opti- 
mal or acceptable control had been achieved for 2 
weeks. Then the dose was gradually reduced accord- 
ing to the guidelines mentioned above. 
During both run-in and the subsequent treatment 
with inhaled budesonide, the children visited the 
clinic every 6 months. At each visit, the number of 
hospital admissions due to acute severe asthma dur- 
ing the previous 6 months, age, height (Harpenden 
stadiometer, mean of three measurements), weight, 
pulmonary function (vitalograph, best of three mea- 
surements), use of concurrent medicine, dose of 
inhaled budesonide, and inhalation device used were 
recorded. Furthermore, it was evaluated whether a 
dose reduction in budesonide should be attempted. 
Between hospital visits, changes in the budesonide 
dose or other asthma medication were always made 
under the supervision of the clinic so that transient 
changes in treatment during periods of worsening of 
asthma symptoms were recorded. In such periods, the 
budesonide dose was normally doubled until asthma 
had been controlled for l-2 weeks. These recordings 
made it possible to calculate the average dose of 
inhaled corticosteroid during the previous 6 months. 
The same two nurses performed all of the measure- 
ments at the clinic between 09.00 h and 15.00 h. 
At each clinic visit the child was seen by the 
same paediatrician. On the day of the clinic visit, 
the children took their normal morning medication 
with the exception of any inhaled &-agonists. Both 
during run-in and during treatment with inhaled 
budesonide, all other asthma medication (except oral 
steroids for more than 2 weeks per year) was allowed. 
Children, who required oral steroids for more than 2 
weeks per year, were excluded from the study. 
Some parents did not want their child on inhaled 
corticosteroids because they were afraid of side 
effects. These children continued in the study on 
their normal regular medication and were not put 
on inhaled corticosteroids. They will be referred to 
as ‘controls’. If the parents of a control child later 
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Table I Demographic data (mean and range) of the two groups of children at the start of the 
run-in period 
Budesonide Controls 
Number 216 62 
Sex (M/F) 148/68 46116 
Age (years) 6.2 (3-l 1) 6.1 (3-11) 
Height (cm) 116 (95-158) 115 (93-l 52) 
Height SDS - 0.093 (- 3.2-3.5) ~0.184 (~2.3-2.3) 
Weight (kg) 22.1 (134-58.3) 20.7 (14.3-48.7) 
Weight SDS -0.18 (-2.7-3.3) - 0.29 (- 2.3-4.1) 
FEV, (% predicted) 81.3 (34-115) 79.2 (37-l 10) 
FMEF (% predicted) 56.2 (25-85) 56.3 (21-89) 
Asthma duration (y) 3.7 (0.5-10) 3.5 (0.5-10) 
Table 2 Use of asthma medication, number of hospital admission due to acute severe asthma, changes in weight and 
height, weight and height standard deviation scores and changes in pulmonary functions in 62 asthmatic children followed 
for 3-7 years without treatment with inhaled cortlcosteroids, and in 216 children followed for 1-3 years without treatment 
with inhaled corticosteroids (run-in) and thereafter 2-6 years on continuous treatment with inhaled budesonide. 
SCG=sodiumcromoglycate. Mean values and 95% confidence limits are given 
Controls Budesonide Budesonide 
(4 run-in (B) treatment (C) A vs. B 
C ~3. A and 
C vs. B 
% on SCG 
% on theophylline 
% on oral &agonist 
Hospitalizations 
(no/child/year) 
d Weight 
(kg year - ‘) 
Prepubertal d weight 
(kg year-‘) 
A Weight SDS 
(change year - ‘) 
A Height 
(cm year ‘) 
Prepubertal A height 
(cm year- ‘) 
A Height SDS 
(change year-‘) 
A FEV, % predicted 
(change year- ‘) 
A FMEF % predicted 
(change year-l) 
58 40 0 NS P~O~OOI 
64 56 12 NS P~O~OOl 
42 46 8 NS P<O.OOl 
0.030 0.026 0.0041 NS P<O.OOl 
3.56 
2.96; 4.16 
3.03 
2.58; 3.48 
0.055 
0.006; 0.116 
5.62 
5.07; 6.17 
5.59 
5.09; 6.09 
- 0.003 
0.044; 0.036 
- 1.17 
-8.1; 5.8 
-7.9 
-18-1; 2.3 
3.48 3.62 
3.13; 3.83 3.20; 4.04 
2.88 2.61 
2.62; 3.14 2.37; 2.85 
0.052 0.03 
- 0.002; O-104 - 0.001; 0.061 
5.59 5.48 
5.41; 5.77 5.31; 5.65 
5.50 5.39 
5.28; 5.72 5.19; 5.59 
- 0.004 -0.012 
- 0.044; 0.036 - -0,035; 0.011 
- 3.09 3.88 
- 15.7; 9.6 2.5; 5.2 
-7.6 2-03 
- 17.6; 2.4 ~ 0.4; 4.5 
NS NS 
NS NS 
NS NS 
NS NS 
NS NS 
NS NS 
NS P=O.O19 
NS P=O.O06 
changed their opinion the child was then put on 
inhaled budesonide as previously described. The 
child continued in the trial and the period without 
inhaled budesonide was used as run-in. The control 
children used diary recordings and PEF monitoring 
in the same manner as the budesonide group. 
At present, more than 200 patients have received 
inhaled budesonide for 22 years in this study. The 
results from these patients and from the control 
patients are presented. The study is presently ongoing 
to follow the patients and others, who at present have 
been on inhaled budesonide for less than 3 years. The 
study will follow the children into adulthood to 
measure their final height, weight, lung function, and 
required dose of budesonide. 
STATISTICS 
In addition to measured values the height and 
weight measurements are presented as height and 
weight standard deviation scores (SDS): 
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Fig. I Daily budesonide dose (mean f SEM) required to maintain asthma control during long term treatment with inhaled 
budesonide. (0 =Nebuhaler, n =Turbuhaler). 
Measured height - predicted height 
SDS = 
Height SD 
Measured values and height and weight SDS were 
compared between and within groups by one-way 
analysis of variance. Changes over time (slopes) in 
the various parameters were assessed by linear regres- 
sion and Wilcoxon’s rank sum test was used to 
compare the slopes. 
Results 
A total of 278 children have completed the run-in 
period; 62 of these are control patients who have not 
taken inhaled corticosteroids for an average of 5.2 
years (range 3-7 years). The remaining 216 children 
have received inhaled budesonide for 2-6 years 
(mean 3.7 years) after a run-in period of l-3 years 
(mean=l.6 years). A total of 3006 hospital visits at 
which the various variables were recorded have now 
been made (729 in the control group and 2275 in the 
budesonide group, of these 678 were during run-in). 
Demographic data for the two groups are given in 
Table 1. There were no statistically significant differ- 
ences in age, height, weight, height SDS, weight SDS, 
pulmonary function, asthma duration or asthma 
treatment between the two groups at the entry to the 
study (Table 2). Throughout the study all 278 chil- 
dren received &agonists morning and evening and 
as needed. After starting on budesonide, no children 
required SCG and the use of slow release theophyl- 
line and oral &agonists was also significantly 
reduced (Table 2). 
HOSPITALIZATIONS 
The number of annual hospitalizations due to 
acute severe asthma was the same in the two groups 
during run-in, before budesonide was started. During 
the subsequent budesonide treatment period, this 
number was markedly reduced whereas no significant 
changes were seen in the control children (Table 2). 
BUDESONIDE DOSE AND DELIVERY SYSTEM 
During the first part of the study period, the 
majority of children in the study group received 
budesonide via a large volume spacer (Nebuhaler). 
During the last part of the period, Turbuhaler 
replaced the Nebuhaler in a large number of children, 
who switched from Nebuhaler to Turbuhaler. The 
mean budesonide dose from the two devices required 
to achieve and maintain asthma control is shown in 
Fig. 1. A statistically significant decrease in the 
budesonide dose was found over time for both inhal- 
ers (P<O.OOl), and the mean dose from Turbuhaler 
(447; 95% confidence limits 420466 pug day- ‘) 
was significantly lower than the mean dose from 
Nebuhaler (612; 95% confidence limits 596-628pg 
day-‘) (P<O.OOl). Yet mean pulmonary functions 
were significantly higher in children using Turbuhaler 
(mean FEV,=98.3 + 14.6% vs. 88.0 f 13.6% in 
Nebuhaler group and mean FMEFz85.7 * 22.1% vs. 
76.8 f 22.8% in Nebuhaler group) (P<O.OOl). 
HEIGHT 
There was a positive correlation between height 
SDS and % predicted FEV, in the controls and in the 
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Fig. 2 Mean height standard deviation scores (SDS) in two groups of children with asthma seen at regular intervals for 3-7 
years. Before time 0 no children received any inhaled corticosteroids. At time 0 one group (216 children=.) started 
continuous treatment with inhaled budesonide. The other group (62 children= n ) continued the treatment given before time 
0. No significant changes in height SDS were seen within or between the two groups. 
budesonide children during run-in (PzO.05; Rz0.126, 
95% confidence limits 0;0.251), indicating that 
asthma severity influenced growth. 
No statistically significant differences were seen 
between the two groups in measured height or height 
SDS at study entry (Table 1, Fig. 2) or at the end of 
the run-in period when mean measured height in the 
two groups was 124 cm (controls) and 125 cm (budes- 
onide). Compared with run-in and with the control 
group treatment, inhaled budesonide did not cause 
any statistically significant changes in growth rate 
during the 3-5 years of treatment (Fig. 2). The 
annual increase in height was 5.62 cm (controls) and 
5.48 cm (budesonide) and the measured height in the 
two groups at the end of the study was 142.5 cm 
(controls) and 143.7 cm (budesonide) (NS). A separate 
analysis of growth rate in prepubertal children gave 
similar results. No statistical significant differences 
were found between the two groups (Table 2). 
Finally, linear regression was used to assess the mean 
annual change in height SDS for each individual child 
over the whole study period. This analysis showed 
that the mean annual change in height SDS was 
similar in the two groups and not significantly 
affected by the budesonide treatment (Table 2). 
Because the dose of budesonide varied in each 
individual child during the treatment period the 
influence of budesonide dose upon growth could not 
be assessed. Therefore, the change in height SDS (A 
SDS) during each 6 months growth interval was 
calculated individually and used to compare budes- 
onide growth rate in three different dose groups 
(~400, 401-800, and >8OOpg day-‘) with the 
growth rate in the control children. No statistically 
significant differences were found. The annual change 
in height SDS (mean and 95% confidence limits) being 
0.011 (- 0.010; 0.034) during run-in, 0.000 (- 0.012; 
0.012) during treatment with ~400 (mean 322) 
pug day-‘, -0.033 (-0.056; -0.010) during treat- 
ment with 401-800 (mean 691) pug day- ‘, - 0.047 
(-0.102; 0,007) during treatment with >800 (mean 
1025) pg day-’ and 0.000 (-0.024; 0.025) during 
control treatment. However, compared with run-in 
and low dose treatment (I 400 pg day- ‘) high doses 
of budesonide (>40O,~g day- ‘) were associated with 
a significant reduction in (d) height SDS (PCO.05). 
Daily doses 1400 pug did not adversely affect growth 
velocity. The number of treatment periods with 
Turbuhaler was too low to allow an accurate analysis 
of each inhaler separately. 
WEIGHT 
A statistically significant correlation between 
weight SDS and % predicted FEV, was seen in the 
control children and budesonide children during 
run-in (P=O.O03; R=0.130, 95% confidence limits 
0.044; 0.214); weight SDS being lower in children with 
low FEV,. There were no statistically significant 
differences between the two groups (d SDS) in these 
parameters (Tables 1 and 2). Measured weight in the 
two groups 3.5 years after the end of run-in was 
36.8 kg (controls) and 38.5 kg (budesonide) (NS). 
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Fig. 3 Changes in lung functions from the run-in period in 216 children treated with inhaled budesonide (0) and 62 
children (W) who received other asthma treatment but no inhaled corticosteroids. Values are mean and 95% confidence 
intervals. 
Separate analysis of weight gain in prepubertal chil- 
dren gave similar results. No statistical significant 
differences were found between the groups. 
PULMONARY FUNCTIONS 
Pulmonary functions were very similar in the two 
groups at study entry. At that time a negative corre- 
lation between % predicted FEV, and the duration of 
asthma was seen (P=O.O7; R= - 0.142; 95% confi- 
dence limits -0.289; 0.012). Both FEV, and forced 
midexpiratory flow (FMEF) showed a statistically 
significant improvement over time during treatment 
with inhaled budesonide (Fig. 3), both when com- 
pared with run-in (P<O.OOl) and with the control 
group (P<O.OOl). The difference was significant after 
only 6 months and it was maintained throughout the 
treatment period. 
Linear regression was used to assess the mean 
slope (annual change) in per cent predicted FEV, for 
each child. There were no statistically significant 
differences between the control children and the 
budesonide children during run-in when no corticos- 
teroids were given (Table 2). The annual increase in 
pulmonary function was significantly higher during 
budesonide treatment than in the same children 
during run-in or than the control children (Table 2). 
Furthermore, the duration of asthma before 
budesonide treatment was started had a marked 
influence upon the rate of annual increase in % 
predicted FEV, and a statistically significant correla- 
tion between the duration of asthma at the start of 
budesonide treatment and the rate of annual increase 
in FEV, was seen (P=O.O2; R= - 0.171, 95% confi- 
dence limits: 0.31; 0.03) (Fig. 4). As a consequence, 
FEV, after 3 years of budesonide treatment was 
lower in children who started budesonide treatment 
more than 5 years after the onset of asthma 
(mean=96.2 + 9.5% predicted) than in children who 
started budesonide l-2 years after onset 
(mean=lOl.O f 13.6% predicted) (PcO.05). At that 
time, mean FEV, in the control group (89.6 * 12.6% 
of predicted) was significantly lower than FEV, in 
the children who started budesonide treatment 
more than 5 years after the onset of asthma. The 
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Asthma duration at start of budesonide (years) 
Fig. 4 Influence of asthma duration at the start of inhaled 
budesonide upon the mean annual increase in FEV, seen 
after budesonide treatment. Mean values and 95% confi- 
dence intervals are shown. 
corresponding figures for FMEF (mean&SD) were 
90.3 f 20% (>.5 years delay), 96.3 f 23% (‘2 years 
delay) and 80.4 f 17% (control group) (PcO.05). This 
effect of delay in budesonide treatment was not 
influenced by the previous asthma treatment given to 
the child. 
The mean age at the start of budesonide treatment 
differed between the five groups in Fig. 4 (4.7, 6.1, 
7.1, 8.2 and 9.3 years, respectively). Therefore, the 
influence of age upon the annual increase in FEV, 
was also evaluated. Similar results (slopes) were 
found in the various age groups, and the age adjusted 
mean annual changes in FEV, also varied signifi- 
cantly with delay in treatment: 8.7, 5.1, 2.3, 3.3 and 
0.9% increase per year in the five delay groups, 
respectively (P=O.O07). For comparison the corre- 
sponding values in children older than 10 years at the 
start of budesonide treatment were: 9.8, 6.2, 3.2, 3.4 
and 2.0% per year. 
Discussion 
The present study evaluated the growth rate in 
children with asthma under controlled conditions in a 
clinical setting. Under these conditions there was no 
indication that long term treatment with inhaled 
budesonide adversely affected growth. This is in 
agreement with the findings in other often less con- 
trolled studies with shorter observation periods and 
lower numbers of patients (48) and a recent prospec- 
tive controlled long term study using a daily budes- 
onide dose of 600,~~g (9). Although the lack of a 
statistical significance on growth does not exclude the 
possibility of an adverse effect, the present study 
would have been sensitive enough to detect a 5% 
reduction in growth rate (3 mm year- ‘) with a statis- 
tical power of ~9.5% in children receiving budesonide 
doses <4OO,ug day-i. So a clinically important 
growth suppression by budesonide in these doses is 
most unlikely. This conclusion is in good agreement 
with the findings in knemometry studies (1 l-13) 
which measure short term changes in lower leg length 
with a high accuracy and which are very sensitive in 
detecting growth reductions since the top of the 
growth suppressive dose-response curve is reached 
already at a daily dose of prednisolone of 2.5 mg (13). 
Although no accurate dose related effects could be 
made the results suggested that high doses around 
800,ag day-’ may to some extent retard growth, 
though not to an extent that was detectable when the 
changes over the whole period were evaluated. In 
agreement with this 2 weeks treatment with 800,~~g 
budesonide day ~ ’ was associated with a marked 
(50%) reduction in lower leg growth rate in knemom- 
etry studies on children with mild asthma (10,ll). So 
further studies in asthmatic children requiring con- 
tinuous long term high dose therapy are needed 
before firm conclusions about such treatment can be 
made. 
It is sometimes suggested that once a child is on 
continuous treatment with inhaled corticosteroids 
there is a possible risk of tachyphylaxis and that over 
the years higher doses (with potential systemic side 
effects) would eventually be needed. The present 
study does not support this. All children were moni- 
tored closely 24 times a year throughout the study 
and the dose of inhaled budesonide was constantly 
tailored to suit the severity of asthma. Under these 
conditions there were no indications of an increase in 
budesonide dose during 3-6 years of continuous 
treatment. In contrast, the dose required to control 
the asthma tended to decrease throughout the study 
period without any loss of asthma control. The initial 
reduction in dose could be due to the treatment 
strategy of starting with a high initial dose and then 
subsequently reducing the dose. However, even after 
the first 6 months a continuous decline in the 
required dose was seen, indicating that once the 
asthma was well controlled, less inhaled corticoster- 
oid was required for maintenance therapy or that the 
severity of asthma tended to decline with age; though 
this did not appear to be the case among the controls. 
At present the influence of treatment upon the 
chance of growing out of the asthma cannot be 
assessed. However, the study is still ongoing and may 
provide such information in the future. 
It was interesting that the children who were 
switched from the Nebuhaler to the Turbuhaler 
device were able to reduce their doses of budesonide 
by 50% and yet experience an improvement in 
asthma control, suggesting that Turbuhaler is more 
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effective than Nebuhaler. This observation agrees 
well with the findings in recent pharmacokinetic 
and pulmonary deposition studies and clinical trials 
(14-17). 
All children suffered from mild and moderate 
asthma according to the generally accepted definition 
of asthma severity, and during run-in they were 
treated according to the normally recommended 
guidelines for these groups of children and the con- 
trols continued this treatment throughout the study 
(3). It was the clinical impression that the majority of 
the children benefited from this treatment. Yet most 
of them showed marked improvements in clinical 
symptoms and pulmonary functions and a substan- 
tial reduction in hospitalization rate due to acute 
severe asthma when they started treatment with 
budesonide. Such marked improvements were unex- 
pected but in good agreement with the findings in 
adults (l&19). This suggests that the degree of 
asthma control achieved by a treatment is often 
overestimated probably because the child’s personal 
best (optimal) control is not assessed as recom- 
mended in the guidelines for adult asthmatics (1,2). 
Paediatric guidelines do not normally emphasize the 
importance of establishing the child’s personal best 
asthma control by an initial period of aggressive 
treatment (3). As a consequence there is a risk that 
the patient is undertreated and symptoms underesti- 
mated because the clinical condition is compared 
with the situation when no treatment is given instead 
of being compared with optimal control. 
It was surprising that treatment induced increases 
in FEV, and FMEF was related to the interval 
between the onset of asthma symptoms at the start of 
inhaled corticosteroid therapy. This effect of delayed 
treatment did not appear to be influenced by the 
previous treatment of the child. This finding in com- 
bination with the negative slope of annual change in 
% predicted FEV, during run-in and control treat- 
ment suggest that suboptimally treated asthma may 
result in irreversible airway obstruction in children. 
Furthermore, it seems that treatment with inhaled 
glucocorticosteroids can reduce this effect or maybe 
even prevent it if the treatment is started early after 
the debut of symptoms. This suggestion agrees well 
with the findings in a recent study: adults with mild 
asthma who were initially treated with inhaled terb- 
utaline for 2 years and then with inhaled budesonide, 
could not achieve as high pulmonary function or as 
good asthma control as a comparable group of 
patients who were treated with inhaled budesonide as 
soon as they were diagnosed (20). Since the effect of 
inhaled glucocorticosteroids seemed to depend upon 
the duration of asthma symptoms before the start of 
treatment these findings suggest that inhaled corticos- 
teroids should be first line treatment not only in 
adults but also in children assessed to suffer from 
mild and moderate asthma. 
Inhaled corticosteroids are the only drugs which 
have been shown in controlled studies to reduce the 
chronic inflammation seen in the airways of asth- 
matic patients (21). Presumably the preserving effect 
on lung function is a result of this effect. Recently, 
however, excessive use of inhaled &agonist has also 
been suspected to adversely affect lung function in 
adults (22-24). Since the use of &agonists was 
markedly reduced by the introduction of budeson- 
ide treatment this mechanism may also have been 
important. 
An accurate cost-benefit analysis was not per- 
formed. However, drug expenses were not higher 
during budesonide treatment and if the effect upon 
asthma control and number of acute admissions was 
considered this analysis also seemed to be in favour 
of the budesonide treatment. 
Conclusion 
Inhaled budesonide in doses up to 400,ug day-’ 
does not stunt long-term growth in children with 
asthma when the dose is regularly tailored to the 
severity of the disease. Early intervention with 
inhaled corticosteroids seems to be able to prevent 
the development of irreversible airway obstruc- 
tion that occurs over the time if the asthma is 
under-treated. Furthermore, compared with other 
treatments early intervention with inhaled 
steroids reduces the risk of undertreatment. Finally, 
Turbuhaler is more effective than Nebuhaler in the 
treatment of asthma in school children. 
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